Collplant biotechnologies announces full-year financial results for 2022 and provides corporate update

Continued advancement of strategic collaboration with abbvie to develop dermal and soft tissue filler products using collplant's recombinant human (rh)collagen additional large-animal study planned in h2 2023 to further 3d bioprinted regenerative breast implant program conference call to be held on march 29, 2023 at 10:00 am u.s. et; dial-in information herein rehovot, israel , march 29, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the full year ended december 31, 2022 and provided a corporate update on its programs. yehiel tal, collplant's chief executive officer, stated, "we remain highly focused on becoming a global leader in regenerative medicine with our pioneering collagen-based platform to help people live longer and better.
CLGN Ratings Summary
CLGN Quant Ranking